The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Therapeutic implications of a novel driver classification system for cutaneous and unknown primary melanomas.
 
Alexander Noor Shoushtari
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Immunocore
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Immunocore; Xcovery
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Francisco Sanchez-Vega
No Relationships to Disclose
 
Havish Kantheti
No Relationships to Disclose
 
Margaret K. Callahan
Employment - Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Celgene (I); Kleo Pharmaceuticals (I)
Consulting or Advisory Role - AstraZeneca; Merck; Moderna Therapeutics
Research Funding - Bristol-Myers Squibb (Inst)
Other Relationship - Clinical Care Options; Potomac Center for Medical Education
 
Michael A. Postow
Honoraria - Bristol-Myers Squibb; Merck
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; Merck; Newlink Genetics; Novartis
Research Funding - Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Rgenix (Inst)
 
Christopher Andrew Barker
Honoraria - Driver Group; Elsevier
Consulting or Advisory Role - Patient Resource; Pfizer
Speakers' Bureau - Omniprex
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Elekta (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Driver Group; Pfizer
 
Walid K. Chatila
No Relationships to Disclose
 
Philip Jonsson
No Relationships to Disclose
 
Charlotte Eielson Ariyan
Employment - Pfizer (I)
Stock and Other Ownership Interests - Pfizer (I)
Speakers' Bureau - Bristol-Myers Squibb
 
Mary Susan Brady
No Relationships to Disclose
 
Daniel G. Coit
No Relationships to Disclose
 
Suresh Nair
Research Funding - Bristol-Myers Squibb (Inst); DNAtrix (Inst); Merck (Inst)
 
Paul B. Chapman
Stock and Other Ownership Interests - Rgenix
Consulting or Advisory Role - Bristol-Myers Squibb; Cell Medica; Genentech/Roche; Immunocore; Merck; Takeda
Research Funding - Pfizer
 
Klaus J. Busam
No Relationships to Disclose
 
David B. Solit
Stock and Other Ownership Interests - Loxo
Consulting or Advisory Role - Illumina; Intezyne Technologies; Loxo; Pfizer; Vividion Therapeutics
Travel, Accommodations, Expenses - Merck KGaA
 
Jedd D. Wolchok
Stock and Other Ownership Interests - Adaptive Biotechnologies; Ascentage Pharma; Beigene; Elucida Oncology; Imvaq Therapeutics; Kleo Pharmaceuticals; Linnaeus Therapeutics; Potenza Therapeutics; Serametrix; Tizona Therapeutics, Inc.; Trieza Therapeutics
Honoraria - American Association for Cancer Research; Esanex; Institut Jules Bordet
Consulting or Advisory Role - Adaptive Biotechnologies; Advaxis; Amgen; Apricity Therapeutics; Array BioPharma; Ascentage Pharma; Astellas Pharma; Bayer; Beigene; Bristol-Myers Squibb; Celgene; Chugai Pharma; F-Star Biotechnology; Genentech; Kleo Pharmaceuticals; Lilly; MedImmune; Merck; Neon Therapeutics; Ono Pharmaceutical; Polaris; Polynoma; Potenza Therapeutics; PsiOxus Therapeutics; PsiOxus Therapeutics; PureTech; Sellas Life Sciences; Serametrix; Surface Oncology; Syndax; Tizona Therapeutics, Inc.; Trieza Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); F-Star Therapeutics; Genentech/Roche (Inst); Incyte (Inst); Leap Therapeutics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst)
Patents, Royalties, Other Intellectual Property - ALPHAVIRUS REPLICON PARTICLES EXPRESSING TRP2; Engineered Vaccinia Viruses for Cancer Immunotherapy; I am a co-inventor and receive royalties for a blood test for monitoring myeloid derived suppressor cells.; I am a co-inventor on a patent for Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy; I am a co-inventor on a patent for CAR+ T cells targeting differentiation antigens as means to treat cancer; I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus.; I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals.; I am co-inventor and receive royalties for a patent for immune modulating antibodies.
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bristol-Myers Squibb; Celgene; Chugai Pharma; Janssen; MedImmune; Novartis; Ono Pharmaceutical; Potenza Therapeutics; Roche; Tizona Therapeutics, Inc.
 
Nikolaus Schultz
No Relationships to Disclose